Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 11/2023

04.10.2023 | Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update

verfasst von: Puneet S. Kang, Ian J. Neeland

Erschienen in: Current Cardiology Reports | Ausgabe 11/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Specific measures of body fat distribution may have particular value in the development and treatment of cardiometabolic conditions, such as cardiovascular disease (CVD) and diabetes mellitus (DM). Here, we review the pathophysiology, epidemiology, and recent advances in the identification and management of body fat distribution as it relates to DM and CVD risk.

Recent Findings

Accumulation of visceral and ectopic fat is a major contributor to CVD and DM risk above and beyond the body mass index (BMI), yet implementation of fat distribution assessment into clinical practice remains a challenge. Newer imaging-based methods offer improved sensitivity and specificity for measuring specific fat depots. Lifestyle, pharmacological, and surgical interventions allow a multidisciplinary approach to reduce visceral and ectopic fat.

Summary

A focus on implementation of body fat distribution measurements into clinical practice should be a priority over the next 5 to 10 years, and clinical assessment of fat distribution can be considered to refine risk evaluation and to develop improved and effective preventive and therapeutic strategies for high-risk obesity.
Literatur
1.
Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;360:1–8.
2.
Ford ES, Capewell S. Proportion of the decline in cardiovascular mortality disease due to prevention versus treatment: public health versus clinical care. Annu Rev Public Health. 2011;32(1):5–22.PubMedCrossRef
3.
Artinian NT, Fletcher GF, Mozaffarian D, Kris-Etherton P, Van Horn L, Lichtenstein AH, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults. Circulation. 2010;122(4):406–41.PubMedPubMedCentralCrossRef
4.
Lichtenstein AH, Appel LJ, Brands M, Carnethon M, Daniels S, Franch HA, et al. Diet and lifestyle recommendations revision 2006. Circulation. 2006;114(1):82–96.PubMedCrossRef
5.
6.
Neeland IJ, Ross R, Després J-P, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715–25.PubMedCrossRef
7.
Lee M-J, Wu Y, Fried SK. Adipose tissue heterogeneity: implication of depot differences in adipose tissue for obesity complications. Mol Aspects Med. 2013;34(1):1–11.PubMedCrossRef
8.
Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001;2(2):73–86.PubMedCrossRef
9.
Lemieux I. Energy partitioning in gluteal-femoral fat: does the metabolic fate of triglycerides affect coronary heart disease risk? Arterioscler Thromb Vasc Biol. 2004;24(5):795–7.PubMedCrossRef
10.
Ibrahim MM. Subcutaneous and visceral adipose tissue: structural and functional differences. Obes Rev. 2010;11(1):11–8.PubMedCrossRef
11.
Mårin P, Andersson B, Ottosson M, Olbe L, Chowdhury B, Kvist H, et al. The morphology and metabolism of intraabdominal adipose tissue in men. Metabolism. 1992;41(11):1242–8.PubMedCrossRef
12.
Joyner JM, Hutley LJ, Cameron DP. Glucocorticoid receptors in human preadipocytes: regional and gender differences. J Endocrinol. 2000;166(1):145–52.PubMedCrossRef
13.
Rebuffé-Scrive M, Lundholm K, Björntorp P. Glucocorticoid hormone binding to human adipose tissue. Eur J Clin Invest. 1985;15(5):267–71.PubMedCrossRef
14.
Hellmér J, Marcus C, Sonnenfeld T, Arner P. Mechanisms for differences in lipolysis between human subcutaneous and omental fat cells. J Clin Endocrinol Metab. 1992;75(1):15–20.PubMed
15.
Arner P, Hellström L, Wahrenberg H, Brönnegård M. Beta-adrenoceptor expression in human fat cells from different regions. J Clin Invest. 1990;86(5):1595–600.PubMedPubMedCentralCrossRef
16.
Koliaki C, Liatis S, Kokkinos A. Obesity and cardiovascular disease: revisiting an old relationship. Metabolism. 2019;92:98–107.PubMedCrossRef
17.
Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab. 2004;1(1):12.CrossRef
18.
Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404.PubMedCrossRef
19.
Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, et al. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012;308(11):1150–9.PubMedPubMedCentralCrossRef
20.
Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, et al. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring). 2013;21(9):E439–47.PubMedCrossRef
21.
Shen W, Middleton MS, Cunha GM, Delgado TI, Wolfson T, Gamst A, et al. Changes in abdominal adipose tissue depots assessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis. J Hepatol. 2023;78(2):238–46.PubMedCrossRef
22.
Cordeiro A, Costa R, Andrade N, Silva C, Canabrava N, Pena MJ, et al. Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity? Clin Res Hepatol Gastroenterol. 2020;44(4):394–402.PubMedCrossRef
23.
Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, et al. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376(7):641–51.PubMedPubMedCentralCrossRef
24.
Salas-Salvadó J, Díaz-López A, Ruiz-Canela M, Basora J, Fitó M, Corella D, et al. Effect of a lifestyle intervention program with energy-restricted mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-Plus trial. Diabetes Care. 2019;42(5):777–88.PubMedCrossRef
25.
Ross R, Soni S, Houle SA. Negative energy balance induced by exercise or diet: effects on visceral adipose tissue and liver fat. Nutrients. 2020;12(4).
26.
Kahleova H, Petersen KF, Shulman GI, Alwarith J, Rembert E, Tura A, et al. Effect of a low-fat vegan diet on body weight, insulin sensitivity, postprandial metabolism, and intramyocellular and hepatocellular lipid levels in overweight adults: a randomized clinical trial. JAMA Netw Open. 2020;3(11): e2025454.PubMedPubMedCentralCrossRef
27.
Rao S, Pandey A, Garg S, Park B, Mayo H, Després JP, et al. Effect of exercise and pharmacological interventions on visceral adiposity: a systematic review and meta-analysis of long-term randomized controlled trials. Mayo Clin Proc. 2019;94(2):211–24.PubMedCrossRef
28.
Unick JL, Beavers D, Bond DS, Clark JM, Jakicic JM, Kitabchi AE, et al. The long-term effectiveness of a lifestyle intervention in severely obese individuals. Am J Med. 2013;126(3):236–42, 42.e1–2.
29.
Jeffery RW, Drewnowski A, Epstein LH, Stunkard AJ, Wilson GT, Wing RR, Hill DR. Long-term maintenance of weight loss: current status. Health Psychol. 2000;19(1s):5–16.PubMedCrossRef
30.
Turk MW, Yang K, Hravnak M, Sereika SM, Ewing LJ, Burke LE. Randomized clinical trials of weight loss maintenance: a review. J Cardiovasc Nurs. 2009;24(1):58–80.PubMedPubMedCentralCrossRef
31.
Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005;82(1 Suppl):222s-s225.PubMedCrossRef
32.
Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54.PubMedCrossRef
33.
Neeland IJ, de Albuquerque RN, Hughes C, Ayers CR, Malloy CR, Jin ES. Effects of empagliflozin treatment on glycerol-derived hepatic gluconeogenesis in adults with obesity: a randomized clinical trial. Obesity (Silver Spring). 2020;28(7):1254–62.PubMedCrossRef
34.
• Gaborit B, Ancel P, Abdullah AE, Maurice F, Abdesselam I, Calen A, et al. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study. Cardiovasc Diabetol. 2021;20(1):57. The SGLT2 inhibitor, empagliflozin, significantly reduced liver fat content and visceral adipose tissue without any effect on myocardial/epicardial fat or myocardial energetics measured with magnetic resonance spectroscopy, potentially rebutting the thrifty substrate hypothesis for cardiovascular benefit of the medication class.PubMedPubMedCentralCrossRef
35.
Hiruma S, Shigiyama F, Hisatake S, Mizumura S, Shiraga N, Hori M, et al. A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: the ASSET study. Cardiovasc Diabetol. 2021;20(1):32.PubMedPubMedCentralCrossRef
36.
•• Neeland IJ, Marso SP, Ayers CR, Lewis B, Oslica R, Francis W, et al. Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: a randomised, double-blind, placebo-controlled, clinical trial. Lancet Diabetes Endocrinol. 2021;9(9):595–605. The GLP-1 receptor agonist, liraglutide, significantly reduced visceral and ectopic body fat and inflammation to a greater degree than expected for weight loss.PubMedCrossRef
37.
Mehta A, Marso SP, Neeland IJ. Liraglutide for weight management: a critical review of the evidence. Obes Sci Pract. 2017;3(1):3–14.PubMedCrossRef
38.
• Sandsdal RM, Juhl CR, Jensen SBK, Lundgren JR, Janus C, Blond MB, et al. Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial. Cardiovasc Diabetol. 2023;22(1):41. Further evidence of a benefit of GLP-1 receptor agonists on body fat distribution and related consequences.PubMedPubMedCentralCrossRef
39.
• Gastaldelli A, Cusi K, FernándezLandó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406. Further evidence of a benefit of GLP-1 receptor agonists on body fat distribution and related consequences.PubMedCrossRef
40.
Zib I, Jacob AN, Lingvay I, Salinas K, McGavock JM, Raskin P, Szczepaniak LS. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. J Investig Med. 2007;55(5):230–6.PubMedCrossRef
41.
Jonker JT, Lamb HJ, van der Meer RW, Rijzewijk LJ, Menting LJ, Diamant M, et al. Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(1):456–60.PubMedCrossRef
42.
Shea MK, Nicklas BJ, Marsh AP, Houston DK, Miller GD, Isom S, et al. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss. Obesity (Silver Spring). 2011;19(8):1636–46.PubMedCrossRef
43.
Kodama N, Tahara N, Tahara A, Honda A, Nitta Y, Mizoguchi M, et al. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(11):4438–45.PubMedCrossRef
44.
Piché ME, Tchernof A, Després JP. Obesity phenotypes, diabetes, and cardiovascular diseases. Circ Res. 2020;126(11):1477–500.PubMedCrossRef
45.
Varma S, Lee CJ, Brown TT, Maruthur NM, Schweitzer M, Magnuson T, et al. Comparative effects of medical versus surgical weight loss on body composition: a pilot randomized trial. Obes Surg. 2019;29(8):2503–10.PubMedCrossRef
46.
Chandra A, Neeland IJ, Berry JD, Ayers CR, Rohatgi A, Das SR, et al. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol. 2014;64(10):997–1002.PubMedCrossRef
47.
Neeland IJ, Gupta S, Ayers CR, Turer AT, Rame JE, Das SR, et al. Relation of regional fat distribution to left ventricular structure and function. Circ Cardiovasc Imaging. 2013;6(5):800–7.PubMedPubMedCentralCrossRef
48.
Wilner B, Garg S, Ayers CR, Maroules CD, McColl R, Matulevicius SA, et al. Dynamic relation of changes in weight and indices of fat distribution with cardiac structure and function: the Dallas Heart Study. J Am Heart Assoc. 2017;6(7).
49.
Neeland IJ, Turer AT, Ayers CR, Berry JD, Rohatgi A, Das SR, et al. Body fat distribution and incident cardiovascular disease in obese adults. J Am Coll Cardiol. 2015;65(19):2150–1.PubMedPubMedCentralCrossRef
50.
Çetin M, Kocaman SA, Durakoğlugil ME, Erdoğan T, Ergül E, Dogan S, Canga A. Effect of epicardial adipose tissue on diastolic functions and left atrial dimension in untreated hypertensive patients with normal systolic function. J Cardiol. 2013;61(5):359–64.PubMedCrossRef
51.
Krishnan A, Sharma H, Yuan D, Trollope AF, Chilton L. The role of epicardial adipose tissue in the development of atrial fibrillation, coronary artery disease and chronic heart failure in the context of obesity and type 2 diabetes mellitus: a narrative review. J Cardiovasc Dev Dis. 2022;9(7).
52.
Warnes CA, Roberts WC. The heart in massive (more than 300 pounds or 136 kilograms) obesity: analysis of 12 patients studied at necropsy. Am J Cardiol. 1984;54(8):1087–91.PubMedCrossRef
53.
Alexopoulos N, Katritsis D, Raggi P. Visceral adipose tissue as a source of inflammation and promoter of atherosclerosis. Atherosclerosis. 2014;233(1):104–12.PubMedCrossRef
54.
Marques MD, Santos RD, Parga JR, Rocha-Filho JA, Quaglia LA, Miname MH, Ávila LF. Relation between visceral fat and coronary artery disease evaluated by multidetector computed tomography. Atherosclerosis. 2010;209(2):481–6.PubMedCrossRef
55.
Ohashi N, Yamamoto H, Horiguchi J, Kitagawa T, Hirai N, Ito K, Kohno N. Visceral fat accumulation as a predictor of coronary artery calcium as assessed by multislice computed tomography in Japanese patients. Atherosclerosis. 2009;202(1):192–9.PubMedCrossRef
56.
Choi S-Y, Kim D, Oh B-H, Kim M, Park HE, Lee C-H, Cho S-H. General and abdominal obesity and abdominal visceral fat accumulation associated with coronary artery calcification in Korean men. Atherosclerosis. 2010;213(1):273–8.PubMedCrossRef
57.
Taguchi R, Takasu J, Itani Y, Yamamoto R, Yokoyama K, Watanabe S, Masuda Y. Pericardial fat accumulation in men as a risk factor for coronary artery disease. Atherosclerosis. 2001;157(1):203–9.PubMedCrossRef
58.
Ding J, Hsu F-C, Harris TB, Liu Y, Kritchevsky SB, Szklo M, et al. The association of pericardial fat with incident coronary heart disease: the Multi-Ethnic Study of Atherosclerosis (MESA)12. Am J Clin Nutr. 2009;90(3):499–504.PubMedPubMedCentralCrossRef
59.
Schlett CL, Ferencik M, Kriegel MF, Bamberg F, Ghoshhajra BB, Joshi SB, et al. Association of pericardial fat and coronary high-risk lesions as determined by cardiac CT. Atherosclerosis. 2012;222(1):129–34.PubMedPubMedCentralCrossRef
60.
Oka T, Yamamoto H, Ohashi N, Kitagawa T, Kunita E, Utsunomiya H, et al. Association between epicardial adipose tissue volume and characteristics of non-calcified plaques assessed by coronary computed tomographic angiography. Int J Cardiol. 2012;161(1):45–9.PubMedCrossRef
61.
Asghar O, Alam U, Hayat SA, Aghamohammadzadeh R, Heagerty AM, Malik RA. Obesity, diabetes and atrial fibrillation; epidemiology, mechanisms and interventions. Curr Cardiol Rev. 2012;8(4):253–64.PubMedPubMedCentralCrossRef
62.
Thanassoulis G, Massaro JM, O’Donnell CJ, Hoffmann U, Levy D, Ellinor PT, et al. Pericardial fat is associated with prevalent atrial fibrillation: the Framingham Heart Study. Circ Arrhythm Electrophysiol. 2010;3(4):345–50.PubMedPubMedCentralCrossRef
63.
Denham NC, Pearman CM, Caldwell JL, Madders GWP, Eisner DA, Trafford AW, Dibb KM. Calcium in the pathophysiology of atrial fibrillation and heart failure. Front Physiol. 2018;9:1380.PubMedPubMedCentralCrossRef
64.
Lin YK, Chen YC, Chen JH, Chen SA, Chen YJ. Adipocytes modulate the electrophysiology of atrial myocytes: implications in obesity-induced atrial fibrillation. Basic Res Cardiol. 2012;107(5):293.PubMedCrossRef
65.
Middeldorp ME, Pathak RK, Meredith M, Mehta AB, Elliott AD, Mahajan R, et al. PREVEntion and regReSsive Effect of weight-loss and risk factor modification on atrial fibrillation: the REVERSE-AF study. Europace. 2018;20(12):1929–35.PubMedCrossRef
66.
Iacobellis G, Gra-Menendez S. Effects of dapagliflozin on epicardial fat thickness in patients with type 2 diabetes and obesity. Obesity. 2020;28(6):1068–74.PubMedCrossRef
67.
•• Novo Nordisk A/S: Semaglutide 2.4 mg reduces the risk of major adverse cardiovascular events by 20% in adults with overweight or obesity in the SELECT trial [Internet]. Bagsværd, Denmark: Novo Nordisk; 2023 Aug 8 [cited 2023 Aug 27]. Available from: https://​www.​novonordisk.​com/​news-and-media/​news-and-ir-materials/​news-details.​html?​id=​166301. First evidence of a cardiovascular benefit for GLP-1 receptor agonists in patients with overweight and obesity but without diabetes, which is the first randomized trial to show a benefit of weight loss on cardiovascular event risk reduction.
68.
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.PubMedPubMedCentralCrossRef
69.
Iacobellis G, Mohseni M, Bianco SD, Banga PK. Liraglutide causes large and rapid epicardial fat reduction. Obesity (Silver Spring). 2017;25(2):311–6.PubMedCrossRef
70.
Vendrell J, El Bekay R, Peral B, García-Fuentes E, Megia A, Macias-Gonzalez M, et al. Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology. 2011;152(11):4072–9.PubMedCrossRef
71.
Sorimachi H, Obokata M, Omote K, Reddy YNV, Takahashi N, Koepp KE, et al. Long-term changes in cardiac structure and function following bariatric surgery. J Am Coll Cardiol. 2022;80(16):1501–12.PubMedPubMedCentralCrossRef
72.
Piché M-E, Clavel M-A, Auclair A, Rodríguez-Flores M, O’Connor K, Garceau P, et al. Early benefits of bariatric surgery on subclinical cardiac function: contribution of visceral fat mobilization. Metabolism. 2021;119: 154773.PubMedCrossRef
73.
Metadaten
Titel
Body Fat Distribution, Diabetes Mellitus, and Cardiovascular Disease: an Update
verfasst von
Puneet S. Kang
Ian J. Neeland
Publikationsdatum
04.10.2023
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 11/2023
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-023-01969-5

Weitere Artikel der Ausgabe 11/2023

Current Cardiology Reports 11/2023 Zur Ausgabe

Heart Failure (HJ Eisen, Section Editor)

Genetic Engineering of Donor Pig for the First Human Cardiac Xenotransplantation: Combatting Rejection, Coagulopathy, Inflammation, and Excessive Growth

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Long-Term Remote vs. Conventional Monitoring of Pacemakers: Systematic Review and Meta-Analysis of Randomized Controlled Trials

Cardio-Oncology (LA Baldassarre, Section Editor)

Advances in Screening for Radiation-Associated Cardiotoxicity in Cancer Patients

Cardiometabolic Disease (DM and CV) (CJ Lavie, Section Editor)

Optimum Dose of Resistance Exercise for Cardiovascular Health and Longevity: Is More Better?

Hypertension (DS Geller and DL Cohen, Section Editors)

New Potential Treatments for Resistant Hypertension

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Artificial Intelligence and Machine Learning Applications in Sudden Cardiac Arrest Prediction and Management: A Comprehensive Review

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen